E
A few months ago, I wrote a bullish article on Ligand (NASDAQ:LGND), with a thesis stating that the company’s outlook should improve with increasing royalty payments and new collaborations using its Captisol technology platform. I also stated that Wall Street is overlooking the fact that Ligand’s partners will spend more than $800 million in R&D in 2014,…